FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2406243329> ?p ?o ?g. }

• W2406243329 endingPage "49" @default.
• W2406243329 startingPage "637" @default.
• W2406243329 abstract "Death still occurs in Hodgkin's disease (HD) patients with advanced stages, but also in early stages. Therefore, the identification of the population of HD patients who would best benefit from an intensification of treatment is a prerequisite in all stages. The best known prognostic factors are bulky mediastinum, B symptoms, and visceral involvement in advanced HD and, in early HD, the number of nodal areas. No satisfactory combination of these factors can clearly identify a group of patients requiring high dose- and potentially risky therapy. Therefore only a very small subgroup of patients with advanced disease (less than 5% of them) calls for intensified regimens, which makes randomized trials very difficult. A large data base, accrued through a cooperative effort and the addition of early stages to advanced stages, would help to clarify the prognostic analysis. In addition, the patient population needs to be selected on the basis of the best therapeutic approach to-date. The analysis parameter should take into account only the failures due to the tumor progression as opposed to those due to a combination of tumor progression and early plus late toxicities. Three successive steps are required to achieve the goal of high-risk patient's treatment optimization. The first is to define, on a well-defined tumor-risk scale, the kind of results that are to be considered as unacceptable when up-to-date conventional strategies are applied. The second is to infer the size of the high-risk population, in inverse ratio to the severity of the risk accepted for normal-risk patients. The third is to tailor the iatrogenic risk, ie the intensity of the high-dose treatment, to the size of the target population and to the anti-tumor benefit that is anticipated. Obviously, the definition of these parameters belongs to the medical decision-makers. Nevertheless, the availability of a quantified tumor-risk scale would allow to elaborate a reliable strategy in patients at risk for failure, lethal toxicity and unbearable health expenses. A collection of adequate recent trial is proposed through the Third International Symposium on Hodgkin's lymphoma in Köln (21-23 September 1995). This effort will be pursued through the International Data Base for Hodgkin's Disease (IDHD). Newer and more efficient strategies may then be designed." @default.
• W2406243329 created "2016-06-24" @default.
• W2406243329 creator A5070508738 @default.
• W2406243329 date "1995-08-01" @default.
• W2406243329 modified "2023-09-23" @default.
• W2406243329 title "[Hodgkin disease: should high-risk patients be selected and chemotherapy be intensified?]." @default.
• W2406243329 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7492820" @default.
• W2406243329 hasPublicationYear "1995" @default.
• W2406243329 type Work @default.
• W2406243329 sameAs 2406243329 @default.
• W2406243329 citedByCount "0" @default.
• W2406243329 crossrefType "journal-article" @default.
• W2406243329 hasAuthorship W2406243329A5070508738 @default.
• W2406243329 hasConcept C126322002 @default.
• W2406243329 hasConcept C141071460 @default.
• W2406243329 hasConcept C143998085 @default.
• W2406243329 hasConcept C168563851 @default.
• W2406243329 hasConcept C177713679 @default.
• W2406243329 hasConcept C2779126056 @default.
• W2406243329 hasConcept C2779134260 @default.
• W2406243329 hasConcept C2908647359 @default.
• W2406243329 hasConcept C71924100 @default.
• W2406243329 hasConcept C99454951 @default.
• W2406243329 hasConceptScore W2406243329C126322002 @default.
• W2406243329 hasConceptScore W2406243329C141071460 @default.
• W2406243329 hasConceptScore W2406243329C143998085 @default.
• W2406243329 hasConceptScore W2406243329C168563851 @default.
• W2406243329 hasConceptScore W2406243329C177713679 @default.
• W2406243329 hasConceptScore W2406243329C2779126056 @default.
• W2406243329 hasConceptScore W2406243329C2779134260 @default.
• W2406243329 hasConceptScore W2406243329C2908647359 @default.
• W2406243329 hasConceptScore W2406243329C71924100 @default.
• W2406243329 hasConceptScore W2406243329C99454951 @default.
• W2406243329 hasIssue "8" @default.
• W2406243329 hasLocation W24062433291 @default.
• W2406243329 hasOpenAccess W2406243329 @default.
• W2406243329 hasPrimaryLocation W24062433291 @default.
• W2406243329 hasRelatedWork W1979814052 @default.
• W2406243329 hasRelatedWork W2069898647 @default.
• W2406243329 hasRelatedWork W2463842169 @default.
• W2406243329 hasRelatedWork W2889468066 @default.
• W2406243329 hasRelatedWork W2899084033 @default.
• W2406243329 hasRelatedWork W2902646137 @default.
• W2406243329 hasRelatedWork W3096266033 @default.
• W2406243329 hasRelatedWork W4239372735 @default.
• W2406243329 hasRelatedWork W4254873301 @default.
• W2406243329 hasRelatedWork W2083697902 @default.
• W2406243329 hasVolume "82" @default.
• W2406243329 isParatext "false" @default.
• W2406243329 isRetracted "false" @default.
• W2406243329 magId "2406243329" @default.
• W2406243329 workType "article" @default.